HER2 and B7-H3 CAR-T cell trials are ongoing with catheter delivery: HER2-positive r-Pediatric CNS tumors (NCT03500991) [126], B7-H3 (NCT04185038) [127], while other target trials are under development at earlier stages. This evidence concerns the gene CD276 and central nervous system neoplasm.